Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net loss was USD 47.52 million compared to USD 41.04 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3255 USD | -0.18% | -15.01% | -93.79% |
May. 21 | Lyra Therapeutics Reduces Workforce to Extend Cash Runway | MT |
May. 21 | Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital | CI |
1st Jan change | Capi. | |
---|---|---|
-93.79% | 19.84M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |